Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCD | Q05655 | 18/20 | 1.00 |
| ▸ | PRKCA | P17252 | 12/20 | 1.00 |
| ▸ | PRKCG | P05129 | 10/20 | 1.00 |
| ▸ | PRKCB | P05771 | 9/20 | 1.00 |
| ▸ | PRKCE | Q02156 | 9/20 | 1.00 |
| ▸ | PRKCH | P24723 | 8/20 | 1.00 |
| ▸ | PRKCQ | Q04759 | 8/20 | 1.00 |
| ▸ | PRKD3 | O94806 | 3/20 | 1.00 |
| ▸ | PRKD1 | Q15139 | 3/20 | 1.00 |
| ▸ | PRKCI | P41743 | 2/20 | 1.00 |
| ▸ | PRKCZ | Q05513 | 2/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Indolactum SCHEMBL1278760 | 1.00 | PRKCD (1.00) | PRKCDPRKCAPRKCGPRKCBPRKCE | |
| Indolactum SCHEMBL1278694 | 1.00 | PRKCD (1.00) | PRKCDPRKCAPRKCGPRKCBPRKCE | |
| SCHEMBL25138542 | 0.90 | PRKCD (0.81) | PRKCDPRKCAPRKCGPRKCBPRKCE | |
| SCHEMBL26998373 | 0.87 | PRKCD (0.77) | PRKCDPRKCAPRKCGPRKCBPRKCE | |
| SCHEMBL29885447 | 0.87 | PRKCD (0.76) | PRKCDPRKCAPRKCGPRKCBPRKCE | |
| SCHEMBL31662410 | 0.83 | PRKCD (1.00) | PRKCDPRKCAPRKCGPRKCBPRKCE | |
| SCHEMBL25138772 | 0.83 | PRKCD (1.00) | PRKCDPRKCAPRKCGPRKCBPRKCE | |
| SCHEMBL30010317 | 0.83 | PRKCD (1.00) | PRKCDPRKCAPRKCGPRKCBPRKCE | |
| SCHEMBL29783196 | 0.82 | PRKCD (0.78) | PRKCDPRKCAPRKCGPRKCBPRKCE | |
| SCHEMBL30010733 | 0.77 | PRKCD (1.00) | PRKCDPRKCAPRKCGPRKCBPRKCE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 141 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12522804-B2 | Method for producing pancreatic β cells | KANEKA CORPORATION (JP) | 2026-01-13 | — | — | US | claimed |
| US-20250092360-A1 | METHODS AND COMPOSITIONS FOR GENERATING SOMATOSTATIN+ INTERNEURONS FROM HUMAN FOREBRAIN NEURAL PROGENITOR CELLS | TRAILHEAD BIOSYSTEMS INC. | 2025-03-20 | — | — | US | claimed |
| WO-2024151804-A2 | METHODS AND MATERIALS FOR GENERATING STEM CELL-DERIVED ENDOCRINE CELL TYPES | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2024-07-18 | — | — | WO | claimed |
| US-11987813-B2 | Microenvironments for self-assembly of islet organoids from stem cells differentiation | The Research Foundation for The Sate University of New York (US) | 2024-05-21 | — | — | US | claimed |
| EP-3825397-B1 | METHOD FOR PRODUCING PARASYMPATHETIC NEURONS | AIST (JP) | 2023-04-19 | — | — | EP | claimed |
| WO-2023033128-A1 | METHOD FOR PRODUCING PROTEIN | 国立大学法人京都大学 | 2023-03-09 | — | — | WO | claimed |
| US-20220226281-A1 | COMPOUNDS FOR USE IN ANTI-CANCER IMMUNOTHERAPY | SIRENAS LLC (US) | 2022-07-21 | — | — | US | claimed |
| EP-3594323-B1 | METHODS AND COMPOSITIONS FOR GENERATING PANCREATIC PROGENITORS AND FUNCTIONAL BETA CELLS FROM HPSCS | UNIV HEALTH NETWORK (CA) | 2026-05-27 | — | — | EP | disclosed |
| CN-116836960-B | Bifunctional enzyme PAI2 with C-N bond and N-N bond synthesis capability, and preparation method and application thereof | QINGDAO INSTITUTE OF BIOENERGY AND BIOPROCESS TECHNOLOGY, CHINESE ACADEMY OF SCIENCES (CN) | 2026-05-26 | — | — | CN | disclosed |
| US-12624342-B2 | Methods for reprogramming cells and uses thereof | GENESIS TECHNOLOGIES LIMITED (BB) | 2026-05-12 | — | — | US | disclosed |
| EP-4471790-B1 | SYSTEM AND METHOD FOR DETERMINING MICROBIOME FROM HOST METABOLOME USING A MACHINE LEARNING MODEL | MICROBIOTX HEALTH PRIVATE LTD (IN) | 2026-04-01 | — | — | EP | disclosed |
| EP-4691479-A2 | GENERATION OF HUMAN PLURIPOTENT STEM CELL DERIVED FUNCTIONAL BETA CELLS SHOWING A GLUCOSE-DEPENDENT MITOCHONDRIAL RESPIRATION AND TWO-PHASE INSULIN SECRETION RESPONSE | Janssen Biotech, Inc. (US) | 2026-02-11 | — | — | EP | disclosed |
| US-12522804-B2 | Method for producing pancreatic β cells | KANEKA CORPORATION (JP) | 2026-01-13 | — | — | US | disclosed |
| WO-2022058758-A1 | DISCONNECTION AGENTS | DC EUROPA LIMITED (GB) | 2022-03-24 | — | — | WO | disclosed |
| EP-3964210-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF ALZHEIMER'S DISEASE | Neurotrope Bioscience, Inc. (US) | 2022-03-09 | — | — | EP | disclosed |
| EP-3954759-A1 | USE OF SMALL MOLECULES TO ENHANCE MAFA EXPRESSION IN PANCREATIC ENDOCRINE CELLS | Janssen Biotech, Inc. (US) | 2022-02-16 | — | — | EP | disclosed |
| CN-114040966-A | Method for producing insulin-producing cell using dihydroindolizinone derivative | 国立大学法人东京工业大学 | 2022-02-11 | — | — | CN | disclosed |
| EP-3946411-A1 | COMPOSITIONS AND METHODS FOR GENETICALLY-ENCODED HIGH VOLTAGE-ACTIVATED CALCIUM CHANNEL BLOCKERS USING ENGINEERED UBIQUITIN LIGASES | The Trustees of Columbia University in the City of New York (US) | 2022-02-09 | — | — | EP | disclosed |
| EP-3950933-A1 | CELL POPULATION INCLUDING PLURIPOTENT STEM CELLS AND PRODUCTION METHOD THEREOF | Kaneka Corporation (JP) | 2022-02-09 | — | — | EP | disclosed |
| US-20220033493-A1 | COMPOSITIONS AND METHODS FOR GENETICALLY-ENCODED HIGH VOLTAGE-ACTIVATED CALCIUM CHANNEL BLOCKERS USING ENGINEERED UBIQUITIN LIGASES | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK | 2022-02-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12624342-B2 | Methods for reprogramming cells and uses thereof | DNMT3B, TRDMT1, MECP2 | PRKCD 2194/4885PRKCA 1578/4885PRKCG 2696/4885 |
| US-20220226281-A1 | COMPOUNDS FOR USE IN ANTI-CANCER IMMUNOTHERAPY | NFATC1, PRKCQ, PRKCZ | PRKCD 11/4885PRKCA 8/4885PRKCG 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.